Shield Therapeutics plc announced the appointment of Hans Peter Hasler as non-executive Chairman of the Company with effect from the Annual General Meeting ('AGM') on 18 June 2020. As announced on 21 May 2020, James Karis, the Company's current Chairman, informed the Company that he would not seek re-election and would be stepping down at the AGM on 18 June 2020. Hans Peter Hasler has therefore been appointed with effect from the AGM. Hans Peter joined Shield's Board of Directors in July 2018 and has served as Chairman of the Nomination Committee and a member of the Audit Committee. Hans Peter has prior executive experience including as Chief Operating Officer at both Elan Corporation and Biogen Inc. as well as Chief Marketing Officer of Wyeth Pharmaceuticals, Radnor, PA. He is non-executive Chairman of the Board of HBM Healthcare Investments AG, Zug/Switzerland and a non-executive director of Minerva Neuroscience Inc., Boston.